Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD)

American Heart Journal

Volumn 131, Issue 2, 1996, Pages 350-355

  Kostis, John B ^a   Shelton, Brent ^b   Gosselin, Gilbert ^c   Goulet, Claude ^c   Hood Jr , William B ^d   Kohn, Robert M ^e   Kubo, Spencer H ^f   Schron, Eleanor ^g   Weiss, Melvin B ^h   Willis III, Park W ⁱ   Young, James B ^j   Probstfield, Jeffrey ^k  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c MONTREAL HEART INSTITUTE   (Canada)

^d UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^h NEW YORK MEDICAL COLLEGE   (United States)

ⁱ MICHIGAN STATE UNIVERSITY   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k USA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; PLACEBO;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; FATIGUE; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERKALEMIA; HYPOTENSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; UREMIA;

EID: 9044222486     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90365-8     Document Type: Article

References (26)

1. Gavras H, Faxon DP, Berkoben J, Brunner HE, Ryan TJ. Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation 1978;58:770-6.
2. Dzau VJ, Colucci WS, Williams GH, Curfman G, Meggs I, Hollenberg NK. Sustained effectiveness of converting enzyme inhibition in patients with severe congestive heart failure. N Engl J Med. 1980;302: 1373-9.
3. Franciosa JA. The use of ACE inhibitors in congestive heart failure. In: Kostis JB, DeFelice EA, eds. Angiotensin converting enzyme inhibitors. New York, NY: Alan R. Liss, 1987:123-48.
4. Ader R, Chatterjee K, Ports T, Brundage B, Hiramatsu B, Parmley W. Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor. Circulation 1980;61:931-7.
5. Awan NA, Evenson MK, Needham KE, Wing A, Mason DT. Efficacy of oral angiotensin-converting enzyme inhibition with captopril therapy in severe chronic normotensive congestive heart failure. AM HEART J 1981;101:22-31.
6. Faxon DP, Halperin JL, Creager MA, Gavras H, Schick E, Ryan TJ. Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy. AM HEART J 1981;101:548-56.
7. Packer M, Medina N, Yushak M, Meller J. Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure. Circulation 1983;68:802-12.
8. Sharpe DN, Murphy J, Coxon R, Hannan SF. Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation 1984;70:271-8.
9. Fitzpatrick D, Nicholls MG, Ikram H, Espiner EA. Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure. Br Heart J 1983;50:163-9.
10. Franciosa JA, Wilen MM, Jordan RA. Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure. J Am Coll Cardiol 1985;5:101-7.
11. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:429-35.
12. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes VC, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:(5):303-10.
13. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
14. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992;327:685-91.
15. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
16. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669-77.
17. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
18. The SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD). Rationale, design and methods: two trials to evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol 1990;66:315-22.
19. Hood WB Jr, Youngblood M, Ghali JK, Reid M, Rogers WJ, Howe D, Teo KK, LeJemtel TH. Initial blood pressure response to enalapril in hospitalized patients (Studies of Left Ventricular Dysfunction [SOLVD]) Am J Cardiol 1991;68:1465-8.
20. Kostis JB, Shelton BJ, Yusuf S, Weiss MB, Capone RJ, Pepine C, Gosselin G, Delahaye F, Probstfield JL, Cahill L, Dutton D. Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of Studies of Left Ventricular Dysfunction (SOLVD). AM HEABT J 1994;128:358-64.
21. Kostis JB. Angiotensin converting enzyme inhibitors. II. Clinical use. AM HEART J 1988;116:1591-605.
22. Packer M, Kessler PD, Gottlieb SS. Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. Postgrad Med J 1986;62(suppl 1):179-82.
23. Parish RC, Miller LJ. Adverse effects of angiotensin converting enzyme (ACE) inhibitors: an update. Drug Saf 1992;7:14-31.
24. Pouleur H, Rousseau MF, van Eyll C, Stoleru L, Hayashida W, Udelson JA, Dolan N, Kinan D, Gallagher P, Ahn S, Benedict CR, Yusuf S, Konstam M, for the SOLVD Investigators. Effects of long-term enalapril therapy on left ventricular diastolic properties in patients with depressed ejection fraction. Circulation 1993;88:481-91.
25. Konstam MA, Kronenberg MW, Rousseau MF, Udelson JE, Melin J, Stewart D, Dolan N, Edens TR, Ahn S, Kinan D, Howe DM, Kilcoyne L, Metherall J, Benedict C, Yusuf S, Pouleur H, for the SOLVD Investigators. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 1993; 88(Part 1):2277-83.
26. Physician's desk reference. Montvale N.J.: Medical Economics Data Production Company, 1994;1558.